skip to content

Cambridge Immunology Network

Cancer of the immune system


Mechanisms of Lymphomagenesis.
Our research aims to dissect out the processes that lead from a healthy immune system to one which harbours a malignancy. We employ a paradigm of lymphomageneis in which a translocation breakpoint product called Nucelophosmin-Anaplastic Lymphoma Kinase (NPM-ALK) drives transformation of T-cells leading to a disease phenotype called Anaplastic Large Cell Lymphoma (ALCL). We are investigating the molecular mechanisms following expression of the NPM-ALK oncogene and presentation of ALCL using mouse models and tissue culture systems. NPM-ALK is a hyperactive tyrosine kinase which activates a plethora of downstream signal transduction pathways some of which are demonstrated in the figure. In addition to refining our knowledge of these pathways we are also investigating the contribution of antigenic stimulation to T-cell lymphomagenesis and its effects on the stability of the genome.


Key publications: 

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.

Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, Pospisilova S.Leukemia. 2020 Nov 27. doi: 10.1038/s41375-020-01093-1. Online ahead of print.PMID: 33247178 No abstract available.


UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group.

Turton P, El-Sharkawi D, Lyburn I, Sharma B, Mahalingam P, Turner SD, MacNeill F, Johnson L, Hamilton S, Burton C, Mercer N.Br J Haematol. 2020 Nov 22. doi: 10.1111/bjh.17194. Online ahead of print.PMID: 33222158



Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy.

Forde S, Matthews JD, Jahangiri L, Lee LC, Prokoph N, Malcolm TIM, Giger OT, Bell N, Blair H, O'Marcaigh A, Smith O, Kenner L, Bomken S, Burke GAA, Turner SD.Br J Haematol. 2020 Sep 3. doi: 10.1111/bjh.17043. Online ahead of print.PMID: 32880915



IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Prokoph N, Probst NA, Lee LC, Monahan JM, Matthews JD, Liang HC, Bahnsen K, Montes-Mojarro IA, Karaca-Atabay E, Sharma GG, Malik V, Larose H, Forde SD, Ducray SP, Lobello C, Wang Q, Luan SL, Pospíšilová Š, Gambacorti-Passerini C, Burke GAA, Pervez S, Attarbaschi A, Janíková A, Pacquement H, Landman-Parker J, Lambilliotte A, Schleiermacher G, Klapper W, Jauch R, Woessmann W, Vassal G, Kenner L, Merkel O, Mologni L, Chiarle R, Brugières L, Geoerger B, Barbieri I, Turner SD.Blood. 2020 Oct 1;136(14):1657-1669. doi: 10.1182/blood.2019003793.PMID: 32573700


Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.

Larose H, Prokoph N, Matthews JD, Schlederer M, Högler S, Alsulami AF, Ducray SP, Nuglozeh E, Fazaludeen FMS, Elmouna A, Ceccon M, Mologni L, Gambacorti-Passerini C, Hoefler G, Lobello C, Pospisilova S, Janikova A, Woessmann W, Damm-Welk C, Zimmermann M, Federova A, Malone A, Smith O, Wasik M, Inghirami G, Lamant L, Blundell TL, Klapper W, Merkel O, Burke GAA, Mian S, Ashankyty I, Kenner L, Turner SD.Haematologica. 2020 Apr 23:haematol.2019.238766. doi: 10.3324/haematol.2019.238766. Online ahead of print.PMID: 32327503 Free article.


The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.

Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD.Nat Commun. 2019 Nov 28;10(1):5428. doi: 10.1038/s41467-019-13315-x.PMID: 31780656 Free PMC article.


Malcolm, T*., Villarese, P*., Fairbairn, C., Lamant, L., Trinquand, A., Hook, C.E., Burke, G.A.A., Brugieres, L., Hughes K., Payet, D., Merkel, O., Schiefer, A., Ashankyty, I., Mian, S., Wasik, M., Turner, M., Kenner, L., Asnafi, V., Macintyre,E. and Turner, S.D.2016) NPM-ALK mimics beta selection enabling thymic escape and peripheral lymphoma development. Nature Communications, 7, Article number: 10087 doi:10.1038/ncomms10087 


Damm-Welk C., Fischer M., Narayanan V, Camidge R., Harris M., Siddiqi F., Burke G.A.A., Lehrnbecher T., Pulford K., Oschlies I., Siebert R., Turner SD* and Woessmann W*. (2016) Anti-ALK-antibodies in patients with ALK-positive malignancies not expressing NPM-ALK.Journal of Cancer, 7(11): 1383-1387. 


Moti, N., Malcolm, T., Hamoudi, R., Mian, S., Garland, G., Hook, C.E., Burke, G.A.A., Wasik, M., Merkel, O., Kenner, L., Laurenti, E., Dick, J.E.and Turner, S.D. (2014) Anaplastic Large Cell Lymphoma stem cells possess a gene expression profile reflective of an early thymic progenitor pointing to a primitive cell of origin. Oncogene, Apr 2;34(14):1843-52. doi: 10.1038/onc.2014.112 


McDuff, F.K.E., Lim, S-V., Dalbay, M. and Turner, S.D.2013) Assessment of the transforming potential of novel Anaplastic Lymphoma Kinase point mutants. Molecular Carcinogenesis52(1):79-83 


Youssif, C., Goldenbogan J., Hamoudi R., Viskaduraki M., Bacon, CM, Burke, A.A and Turner S.D. (2009) Genomic profiling of pediatric ALK-positive Anaplastic Large Cell Lymphoma – a Children’s Cancer and Leukaemia Group study. Genes Chromosomes and Cancer 

Cui Y., Kerby A., McDuff F.K.E. and Turner S.D. (2009) NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing malignancies. Blood. 113(21):5217-5227.


Turner S.D.,Yeung D., Hadfield K., Cook S.J. and Alexander D.R. (2007) The NPM-ALK Tyrosine Kinase Mimics TCR Signalling Pathways Inducing NFAT and AP-1 by Ras-Dependent Mechanisms. Cellular Signaling. 19(4):740-47. 


Turner S.D.,Tooze R.M., Macklennan K., Alexander D.R. (2003) Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22:7750-7761


Other publications: 

Haque, M., Li,J., Huang, Y-H.,Almowaled, M., Barger, C.J., Karpf,A.R., Wang, P., Chen, W., Turner, S.D.and Lai, R. (2019) NPM-ALK is a key regulator of the oncoprotein FOXM1 in ALK-positive anaplastic large cell lymphoma: identification of a novel role for NPM1 in the pathobiology of NPM-ALK. CancersIn press 

Prutsch, N., Suske, T., Liang, H.C., Wu, L., Simonitsch- Klupp, I., Alvarez-Hernandez, A., Gurnhofer, E., Schlederer, M., Roos, S., Kornauth, C., Leone, D., Aufinger, A., Hielscher, T., Aberger, F., Stoiber, D., Strobl, B., Müller, M., Jäger, U., Staber, P., Grebien, F., Moriggl, R., Inghirami, G., Sanda, T., Look, A.T., Turner, S.D.,Kenner, L. and Merkel, O. (2018) Dependency on the TYK2/STAT1/MCL1 axis in Anaplastic Large Cell Lymphoma. Leukemia Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. 

Schleussner, N.,Merkel, O., Hummel, F., Costanza, M., Huan-Chang Liang, H-C., Romagnani, C., Durek, P., Anagnostopoulos, I., Hummel, M., Jöhrens, K., Niedobitek., A, Griffin, P.R., Woessmann, W., Damm-Welk, C., Hinze, C., Stoiber, D., Gillissen, B.,Turner, S.D.,Kaergel, E., von Hoff, L., Grau, M., Lenz, G., Dörken, B., Scheidereit, C., Kenner, L., Janz, M., and Mathas, S. (2017) The AP-1 -BATF and -BATF3 module is essential for growth, survival and TH17 / ILC3 skewing of anaplastic large cell lymphoma. Leukemia 321994–2007doi: 10.1038/s41375-018-0045-9

Lewis, S., Gardner, M., Higgins, J., Holly, J., Gaunt, T., Perks, C., Turner, S.D.,Rinaldi, S., Thomas, S., Harrison, S., Lennon, R., Tan, V., Borwick, C., Emmett, P., Jeffreys, M., Northstone, K., Mitrou, G., Wiseman, M., Thompson, R., Martin, R.M. (2017) Developing the WCRF International/University of Bristol methodology for identifying and carrying out systematic reviews of mechanisms underpinning exposure-cancer associations.Cancer Epidemiology, Biomarkers and Prevention Nov;26(11):1667-1675. doi: 10.1158/1055-9965.EPI-17-0232. Epub 2017 Oct 4.

Johnson, L., O’Donoghue, J.M., McLean, N., Turton, P., Khan, A.A., Turner, S.D.,Lennard, A., Collis, N., Butterworth, M., Gui, G., Bristol, J., Hurren, J., Smith, S., Grover, K., Spyrou, G., Krupa, K., Azmy, I.A., Young, I.E., Staiano, H., Khalil J.J., and MacNeill, F.A. (2017)Breast Implant Associated Anaplastic Large Cell Lymphoma: The UK experience. Recommendations on its management and implications for informed consent. European Journal of Surgical OncologyAug;43(8):1393-1401. doi: 10.1016/j.ejso.2017.05.004

Harrison, S., Lennon R., Holly J., Higgins J., Gardner M., Perks C., Gaunt T., Tan V., Borwick C., Emmett P., Jeffreys M., Northstone K., Rinaldi S., Sterne J., Thomas S., Turner S.D., Pease A., Vilenchik V., Martin, R.M., and Lewis S.J. (2017) Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis. Cancer Causes and Control Jun;28(6):497-528. doi: 10.1007/s10552-017-0883-1

Hassler, M.R., Pulverer, W., Redl, E., Hacker, J., Garland, G., Schiefer, A., Simonitsch-Klupp, I., Kenner, L., Weinhäusel, A., Turner, S.D.and Egger, G. (2016)ALK-dependent transcription factor networks are associated with epigenomic alterations of DNA methylation in ALCL. Cell Reports 17(2):596-608. doi: 10.1016/j.celrep.2016.09.018 

Ceccon M., Boggio Merlo E., Mologni L., Poggio T., Varesio L.M., Menotti M., Bombelli S., Rigolio R., Manazza A.D., Ambrogio C., Giudici G., Casati C., Mastini C.,  Compagno M., Turner S.D., Gambacorti-Passerini C., Voena C. and Chiarle R. (2015)  Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene, doi: 10.1038/onc.2015.456 

Pencik, J., Schlederer, M., Gruber, W., Aberger, F., Kennedy, R., Walker, S.M., Malcolm, T., Turner, S.D.,Rose-John, S., Chalaris, A., Levy, D.E., Marié, I.J., Hassler, M.R., Poli, V., Unger, C., Eferl, R., Esterbauer, H., Aksoy, O., Tahereh, J., Skucha, A., Grebien, F., Herac, M., Mazal, P., Haitel, A., Susani, M., Moriggl, R., Dolznig, H., Culig, Z.& Kenner, L.(2015)Loss of IL-6/Stat3 signaling drives prostate cancer progression in mice and men. Nature Communications Jul 22;6:7736. doi: 10.1038/ncomms8736.

Merkel, O., Hamacher, F., Griessl, R., Grabner, L., Schmatz, A., Prutsch, N., Baer, C., Hartmann, T., Simonitsch, I., Plass, C., Turner, S.D., Zenz, T., Greil, R. and Kenner, L. (2015) Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J. Path Aug;236(4):445-56. doi: 10.1002/path.4539. 

Marzec M., Halasa K., Liu X., Cheng M., Baldwin D., Tobias J.W., Schuster S., Woetmann A., Turner S.D.,Odum N., and Wasik M.A. (2013) Malignant transformation of CD4+T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming. Journal of Immunology191(12):6200-7 

Laimer, D., Dolznig, H., Kollmann, K., Vesely, P.W., Schlederer, M., Merkel, O., Schiefer, A., Hassler, M.R., Heider, S., Amenitsch, L., Thallinger, C., Staber, P.B., Simonitsch-Klupp, I., Artaker, M., Lagger, S., Turner, S.D.,Pileri, S., Piccaluga, P.P., Valent, P., Messana, K., Landra, I., Weichhart, T., Knapp, S., Shehata, M., Todaro, M., Sexl, V., Höfler, G., Piva, R., Medico, E., Riggeri, B.A., Cheng, M., Eferl, R., Egger, G., Penninger, J.M., Jaeger, U., Moriggl, R., Inghirami, G.and Kenner, L. (2012)Identification of PDGFR blockade as a rational and highly effective therapy for NPM-ALK driven lymphomas. Nature Medicine 18(11):1699-704 

Zhang, Q., Wang, HY., Kantekure, K., Paterson, JC., Liu, X., Schaffer, A., Paulos, C, Milone, MC., Odum, N., Turner, SD.,Marafioti, T., Wasik, MA. (2011) Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.   Blood 118(11):3062-71. 

Martinelli, P., Bonetti, P., Sironi, C., Pruneri, G., Fumagalli, C., Raviele, PR., Volorio, S., Pileri, S., Chiarle, R., Khoramian Tusi, B., McDuff, F.K.E., Turner, S.D.,Inghirami, G., Pelicci, P.G. and Colombo, E.(2011) The lymphoma-associated NPM-ALK oncogene elicits a p16INKa/pRb-dependent tumour-suppressive pathway. Blood 117(24):6617-26.

McDuff F.K.E., Hook C.E., Tooze R., Huntly B.J. Pandolfi P.P. and Turner S.D.(2011) Determining the Contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis. Lab Investigation doi: 10.1038/labinvest.2011.96 

McDuff F.K.E and Turner S.D.(2011) Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest in the Absence of Detectable p53 Stabilization. PLOS One6(3): e17854. doi:10.1371/journal.pone.0017854

Merkel, O., Hamacher, F., Laimer, D., Scheideler, M., Trajanoski, Z., Egger, G., Turner, SD., Greil, R. and Kenner, L. (2010) Diacritic and functionally active microRNAs in both ALK+and ALK-ALCL. PNAS 107(37):16228-33 

Rigby S., Huang Y., Streubel B., Chott A., Du M-Q., Turner S.D.and Bacon C.M. (2009) The lymphoma associated fusion tyrosine kinase Itk-Syk requires Pleckstrin homology domain-mediated membrane localization for activation and cellular transformation. JBC

Turner S.D.,Merz H., Yeung D., Alexander D.R. (2006) CD2 Promoter Regulated Nucleophosmin-Anaplastic Lymphoma Kinase in Transgenic Mice Causes B Lymphoid Malignancy. Anticancer Research 26(5A):3275-79.

Turner S.D.,Tinwell H., Piegorsch W., Schmezer P., Ashby J. (2001) The Non-Genotoxic Carcinogens Limonene and Sodium Saccharin are not Mutagenic to BigBlue Transgenic Male Rats. Mutagenesis16:329-332.

Turner S.D.,Fairbairn L.J., Rafferty J.A., Ashby J., Tinwell H., Vrieling H., Wijnhoven S.W.P. and Lashford L.S. (2001) Assays to Predict the Genotoxicity of Etoposide; Focusing on the Best Assay. Mutation Research 493:143-151. 

Turner S.D., Fairbairn L.J., Rafferty J.A., Ashby J., Tinwell H. and Lashford L.S. (2000) MDR-1 Transduction Protects Against the Potential Mutagenic Effects of Etoposide Exposure. Leukemia 14:1796-1802

Rajaguru P., Fairbairn L.J., Ashby J., Willington M.A., Turner S.D.,Woolford L.A., Chinnasamy N. and Rafferty J.A. (1999) Genotoxicity Studies on the Azo Dye Direct Red 2 Using the in vivoMouse Bone Marrow Micronucleus Test. Mutation Research 444: 175-180.

Turner, S.D., Inghirami, G.I., Mirando, R.M. and Kadin, M (2019) Cell of origin and immunological events in the pathogenesis of BIA-ALCL. American Journal of Pathology, In press 

Ducray, S.P., Natarajan, K., Garland, G.D., Turner, S.D.*Egger, G.*The transcriptional roles of ALK fusion proteins in tumorigenesis. Cancers, In press

Turner, S.D.(2019) Commentary on: Deposition of Host Matrix Proteins on Breast Implant Surfaces Facilitates Staphylococcus Epidermidis Biofilm Formation: In Vitro Analysis. Aesthetic Surgery Journal, pii: sjz144. doi: 10.1093/asj/sjz144

Trigg, R.M., Shaw, J.A. and Turner, S.D.(2019) Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biology, 9(5):190056. doi: 10.1098/rsob.190056

Fritzal, F.,Turner, S.D.* and Kenner, L.* (2019) Is Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) a Hazard of Breast Implant Surgery? Open Biology, 9(4):190006. doi: 10.1098/rsob.190006

Turner, S.D.and Wright, P. (2019) Commentary on: Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthetic Surgery Journal, 1-2, DOI: 10.1093/asj/sjz025 

Turner, S.D.(2019) Anaplastic Large Cell Lymphoma: chapter in Non-Hodgkin Lymphoma in Childhood and Adolescence, Springer International PublishingDOI:10.1007/978-3-030-11769-6,eBook ISBN: 978-3-030-11769-6, Hardcover ISBN:978-3-030-11768-9

Larose, H., Burke, G.A.A., Lowe, E. and Turner, S.D.(2019) From Bench to Bedside: The past, present and future of therapy for systemic paediatric ALCL, ALK+ British Journal of Haematology, doi: 10.1111/bjh.15763.

Turner, S.D.(2019) Anaplastic Large Cell Lymphoma, book chapter in INTech Open access Peripheral T cell lymphoma, DOI: 10.5772/intechopen.81382 

Turner, S.D.(2019)The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis. Aesthetic Surgery Journal, 39 (Supplement 1):S21-S27. doi: 10.1093/asj/sjy229

Trigg, R.M. and Turner, S.D. (2018) ALK in neuroblastoma: biological and therapeutic implications. Cancers 10(4). pii: E113. doi: 10.3390/cancers10040113

Garces de los Fayos AlonsoI., Liang, H-C., Turner, S.D., Lagger, S., Merkel, O., Kenner, L. (2018) The role of Activator Protein-1 (AP-1) family members in CD30 positive lymphomas. Cancers 10(4), 93; doi:10.3390/cancers10040093

Prokoph, N., Larose, H., Lim, M., Burke, G.A.A. and Turner, S.D. (2018)Treatment options for paediatric ALCL: Current standard and beyond. Cancers 10(4), 99; doi:10.3390/cancers10040099

Turner, S.D. (2017)An exploration into the origins and pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-positive Cancers, 9(10), 141; doi:10.3390/cancers9100141

Merkel, O., Morrigl, R.,Turner, S.D. and Kenner, L. (2017) When the guardian sleeps: Reactivation of the p53 pathway in cancer. Mutation Research Reviews, Jul;773:1-13. doi: 10.1016/j.mrrev.2017.02.003

Turner, S.D. and Egger, G. (2017) New avenues for targeted therapies and biomarkers in anaplastic large cell lymphoma. Epigenomics, Feb;9(2):97-100. doi: 10.2217/epi-2016-0159

Malcolm, T., Hodson, D.J., Macintrye E.A. and Turner, S.D.(2016) Challenging perspectives on the cellular origin of lymphoma. Open Biology, 6(9). pii: 160232

Turner, S.D., Lamant, L., Kenner, L. and Brugieres, L. (2015) Anaplastic Large Cell lymphoma: biology and clinical application. British Journal of Haematology, 173(3):560-72, doi: 10.1111/bjh.13958. 

Merkel, O., Kenner, L. and Turner, S.D.(2015) Hunt for stem cells in NHL Oncoscience

Giuriato, S and Turner, S.D.(2015) Twenty years of modelling NPM-ALK induced Lymphomagenesis. Frontiers in Bioscience(Schol. Ed). 2015 Jun 1;7:248-259. 

Ye X., Shokrollahi K., Rozen W.M., Whitaker I.S.,*and Turner S.D.*(2014)Anaplastic Large Cell Lymphoma (ALCL) and Breast Implants: Breaking down the evidence  Mutation Research – Reviews, 762C:123-132. 

Turner S.D.(2013) Inimitable Imatinib: The range of targeted tumours expands to include T-cell malignancies. Leukemia 27(4):759. 

Merkel, O., Kenner, L. and Turner S.D.(2011) Anaplastic Large Cell Lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28thJune 2011. Leukemia 25:1795–1796 

McDuff F.K.E and Turner S.D.(2011) Jailbreak: oncogene induced senescence and its evasion. Cellular Signalling 23(1):6-13 

Turner S.D.,Alexander, D.R. (2006) Fusion Tyrosine Kinase Mediated Signalling Pathways in the Transformation of Haematopoietic Cells. Leukemia 20:572-582 

Turner S.D.and Alexander D.R. (2005) What have we learnt from mouse models of NPM-ALK induced lymphomagenesis? Leukemia19:1128-113 

Rafferty J.A., Lashford L.S., Turner S.D.and Fairbairn L.J. (1999) Genetic Chemoprotection of Bone Marrow from the Dose-Limiting Toxicities of Chemotherapy. Progress in Growth Factors 5: 3-7.


Other Professional Activities

Public Involvement/Engagement

  • Scientific advisor to Francesca’s Research Fund, 2017-
  • Scientific advisor to the Alex Hulme Foundation, 2012 - ‘The Great Implant Scandal’

  • Cam105FM Science Show interview 16/9/18
  • BBC Radio 4 You and Yours Interview 6/6/17
  • Talking Heads video for Association of Breast Surgeons 16/11/16
  • BBC Radio 4 Women’s Hour interview 14/11/16
  • Talk given at CRUK race for life event, Ickworth park, 17th September 2016
  • Address to Francesca Richardson Fund Charity Ball 10/09/16
  • Contributed to Daily Mail article on breast implant associated ALCL July 24 2016
  • Quotes given to Canadian TV ( August 2016
  • Interview on BBC Radio 4 You and Yours consumer programme 23/6/16
  • Interview on radio five live with Adrian Chiles 14/6/16
  • Talk to patient voices advocacy group 10/6/16
  • Talk to CRUK kids and teens TK MAXX fundraising team and volunteers at CRUK charity shops 02/16
  • Cambridge University Science Festival 2009, 2010, 2012, 2013, 2015, 2018. One-day event in which the public are invited to attend our laboratory and experience our research. We present a varied array of activities to inspire children and adults including ‘making fake blood, can you find all the cells that make up our blood?, design a white blood cell cookie and others’
  • Cambridge University Science Festival Schools Road show 2011
  • Leukaemia and Lymphoma Research (Bloodwise) open days and other fundraising activities
  • July 2011 Lymphoma Association patient support group meeting presentation and talk
  • September 2011 – hosted lymphoma association patient support group for a lab open day
  • April 2012 – Beefy’s great British Walk
  • July 2012 – talk given to a Women’s Institute group in Royston, Herts
  • March 2013 – talk given to trainee therapeutic radiographers, University Campus Suffolk, Ipswich
  • 16 May 2013 ‘Pint of Science’ talk to the general public in the Panton Arms pub, Cambridge;!cambridge/cglt
  • Address to the Alex Hulme Foundation annual ‘star ball’, Manchester 2012-2019, 100 Club Business networking event 4/3/16.
  • Address to ‘Damo’s Big Charity Ball’ (in aid of Addenbrooke’s Hospital and Leukaemia and Lymphoma Research), Wyboston Lakes, Cambridge, February 2014
  • Address to Biennual Dragon boat race, Chelmsford, Essex, 22 May 2014, 10 May 2016.
  • Address to Newmarket Academy March 2015
Dr Suzanne Dawn Turner
Takes PhD students
Available for consultancy


Departments and institutes: 
Person keywords: 
animal models
Naïve T cells
T helper cells
B cells
T lymphocyte
T cell differentiation
T cells
TCR triggering
Recent Thymic Emigrants (RTE)
T cell receptor (TCR)